Michael Heinrich, MD - Optimally Sequencing Modern TKIs in GIST: Expert Perspectives From an Interprofessional Sarcoma Team

Michael Heinrich, MD - Optimally Sequencing M...

Up next

Natasha B. Leighl, MD, MMSc, FRCPC, FASCO, FCAHS - Real Talk on Directions and Decisions in the Clinical Management of EGFRm NSCLC: Optimizing the Patient Journey Throughout the Disease Continuum

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE informatio ...  Show more

Javier Morales, MD, FACP, FACE - Bridging Knowledge to Action: Translating Evidence Into Practice for Type 2 Diabetes Management

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to ...  Show more

Recommended Episodes

Tanios Bekaii-Saab, MD - Dialing in the Dose: Reviewing Recent Evidence and Team-Based Strategies to Personalize and Optimize Patient Care in Metastatic Colorectal Cancer
PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Go online to PeerView.com/GVA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Successfully and safely delivering optimized care in metastatic colorectal cancer (mCRC) can be a challenge, particularly during later lines of the ...  Show more

Bradley J. Monk, MD, FACS, FACOG - When Are PARP Inhibitors the Best Choice for Patients With Ovarian Cancer? Personalizing Therapeutic Selection Across the Disease Continuum
PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Go online to PeerView.com/YWA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you optimizing the care of your patients with ovarian cancer with poly (ADP-ribose) polymerase (PARP) inhibitors and novel therapies such as tu ...  Show more

Pasi A. Jänne, MD, PhD - Addressing Key Targets in Advanced NSCLC: Evaluating the Latest Evidence and Clinical Opportunities for HER2-, HER3-, and TROP2-Targeted Therapies
PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Go online to PeerView.com/ZGP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The treatment arsenal for non–small cell lung cancer (NSCLC) with and without genomic alterations continues to expand, and novel HER2-, HER3-, and ...  Show more

Bhavana Pothuri, MD, MS - Expanding the Benefits and Refining the Role of Immune Checkpoint Inhibitors in the Treatment of Recurrent and Advanced Endometrial Cancer
PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Go online to PeerView.com/KWF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in oncology discusses the role of immune checkpoint inhibitors in the care of patients with recurrent and advanced endo ...  Show more